High rate of durable remissions post autologous stem cell transplantation for core-binding factor acute myeloid leukaemia in second complete remission
Bone Marrow Transplant
.
2020 Nov;55(11):2207-2210.
doi: 10.1038/s41409-020-0924-3.
Epub 2020 May 6.
Authors
Matthew J Rees
1
,
Andrew Spencer
2
,
Peter Browett
3
,
Frank Alvaro
4
,
Duncan Purtill
5
,
Julie Crawford
6
,
Sam Milliken
7
,
Hock Lai
8
,
Humphrey Pullon
9
,
Andrew Grigg
10
Affiliations
1
Department of Clinical Haematology, Austin Health, Melbourne, VIC, Australia.
[email protected]
.
2
Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC, Australia.
3
Department of Haematology, Auckland Hospital, Auckland, New Zealand.
4
Department of Haematology, John Hunter Children's Hospital, Newcastle, NSW, Australia.
5
Department of Haematology, Fiona Stanley Hospital, Perth, WA, Australia.
6
Department of Haematology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
7
Department of Haematology, St Vincent's Hospital, Sydney, NSW, Australia.
8
Department of Haematology, Townsville Hospital, Townsville, QLD, Australia.
9
Department of Haematology, Waikato Hospital, Hamilton, New Zealand.
10
Department of Clinical Haematology, Austin Health, Melbourne, VIC, Australia.
PMID:
32376971
DOI:
10.1038/s41409-020-0924-3
No abstract available
Publication types
Letter
MeSH terms
Core Binding Factors
Hematopoietic Stem Cell Transplantation*
Humans
Leukemia, Myeloid, Acute* / therapy
Remission Induction
Stem Cell Transplantation
Transplantation, Autologous
Substances
Core Binding Factors